Inhibition of NaV1.8 prevents atrial arrhythmogenesis in human and mice

Basic Res Cardiol. 2020 Feb 20;115(2):20. doi: 10.1007/s00395-020-0780-8.

Abstract

Pharmacologic approaches for the treatment of atrial arrhythmias are limited due to side effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical interest. Recent genome studies suggested an involvement of SCN10A sodium channels (NaV1.8) in atrial electrophysiology. This study investigated the role and involvement of NaV1.8 (SCN10A) in arrhythmia generation in the human atria and in mice lacking NaV1.8. NaV1.8 mRNA and protein were detected in human atrial myocardium at a significant higher level compared to ventricular myocardium. Expression of NaV1.8 and NaV1.5 did not differ between myocardium from patients with atrial fibrillation and sinus rhythm. To determine the electrophysiological role of NaV1.8, we investigated isolated human atrial cardiomyocytes from patients with sinus rhythm stimulated with isoproterenol. Inhibition of NaV1.8 by A-803467 or PF-01247324 showed no effects on the human atrial action potential. However, we found that NaV1.8 significantly contributes to late Na+ current and consequently to an increased proarrhythmogenic diastolic sarcoplasmic reticulum Ca2+ leak in human atrial cardiomyocytes. Selective pharmacological inhibition of NaV1.8 potently reduced late Na+ current, proarrhythmic diastolic Ca2+ release, delayed afterdepolarizations as well as spontaneous action potentials. These findings could be confirmed in murine atrial cardiomyocytes from wild-type mice and also compared to SCN10A-/- mice (genetic ablation of NaV1.8). Pharmacological NaV1.8 inhibition showed no effects in SCN10A-/- mice. Importantly, in vivo experiments in SCN10A-/- mice showed that genetic ablation of NaV1.8 protects against atrial fibrillation induction. This study demonstrates that NaV1.8 is expressed in the murine and human atria and contributes to late Na+ current generation and cellular arrhythmogenesis. Blocking NaV1.8 selectively counteracts this pathomechanism and protects against atrial arrhythmias. Thus, our translational study reveals a new selective therapeutic target for treating atrial arrhythmias.

Keywords: Antiarrhythmic drugs; Atrial arrhythmias; Late sodium current; Na+ channel.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / drug effects
  • Aged
  • Aniline Compounds / pharmacology*
  • Animals
  • Anti-Arrhythmia Agents / pharmacology*
  • Arrhythmias, Cardiac / genetics
  • Arrhythmias, Cardiac / metabolism
  • Arrhythmias, Cardiac / physiopathology
  • Arrhythmias, Cardiac / prevention & control*
  • Cells, Cultured
  • Disease Models, Animal
  • Female
  • Furans / pharmacology*
  • Heart Rate / drug effects*
  • Humans
  • Male
  • Mice, Knockout
  • Middle Aged
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • NAV1.8 Voltage-Gated Sodium Channel / drug effects*
  • NAV1.8 Voltage-Gated Sodium Channel / genetics
  • NAV1.8 Voltage-Gated Sodium Channel / metabolism
  • Picolinic Acids / pharmacology*
  • Sodium Channel Blockers / pharmacology*

Substances

  • 6-amino-5-(2,3,5-trichlorophenyl)pyridine-2-carboxylic acid methylamide
  • A 803467
  • Aniline Compounds
  • Anti-Arrhythmia Agents
  • Furans
  • NAV1.8 Voltage-Gated Sodium Channel
  • Picolinic Acids
  • SCN10A protein, human
  • Scn10a protein, mouse
  • Sodium Channel Blockers